Filing Analysis
Other SEC Filing
Filed Apr 30, 2026
LOW
Insight Molecular Diagnostics Inc. filed this 8-K to correct a clerical error in its Third Amended and Restated Bylaws previously filed with its 2025 Annual Report. The original exhibit inadvertently included incorrect shareholder voting provisions that were not part of the actual bylaws.
Red Flags
- Clerical error in a primary governing document (Bylaws) suggests potential lapses in administrative oversight or legal review of SEC filings.
Key Facts
- The company filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, on March 26, 2026.
- Exhibit 3.5 of the 10-K contained a clerical error regarding shareholder voting provisions.
- The company is filing the corrected Third Amended and Restated Bylaws as Exhibit 3.1 to this 8-K.
- The correction does not change any other disclosures contained in the previously filed Form 10-K.
Regulation FD Disclosure
Filed Mar 26, 2026
LOW
Insight Molecular Diagnostics Inc. (IMDX) furnished its financial results for the quarter and fiscal year ended December 31, 2025, via a press release on March 26, 2026.
Key Facts
- Announced financial results for the "three and twelve months ended December 31, 2025"
- Press release furnished as Exhibit 99.1
- Reported on March 26, 2026, under Item 2.02 Results of Operations and Financial Condition
Material Agreement
Filed Feb 26, 2026
MEDIUM
Insight Molecular Diagnostics Inc. (IMDX) entered into a Specimen Collection Agreement with Quest Diagnostics for its GraftAssureCore™ blood test. The agreement includes a provision for both parties to negotiate in good faith for additional rights to the GraftAssure technology.
Key Facts
- Agreement entered on February 20, 2026, with Quest Diagnostics Incorporated.
- Quest will provide specimen collection services for IMDX's GraftAssureCore™ test, which measures donor-derived cell free DNA (dd-cfDNA).
- IMDX will pay fees to Quest for services rendered.
- The parties agreed to a specified period to negotiate additional rights to the GraftAssure technology.
- The full text of the agreement was not included but is expected in a future filing.
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.